

SNG001: A clinical stage broad-spectrum antiviral therapeutic

Designed to address a very high unmet medical need in a range of clinical indications

Patients with critical respiratory virus infections have very few therapeutic options.

For example, mortality in patients with respiratory virus infections who require admission to intensive care and mechanical ventilation can exceed 40%.

Moreover, clinical outcomes are worse in the ever-increasing elderly population and in other groups of hospitalised patients, such as the immunocompromised.


Further meaningful therapeutic opportunities exist in other diseases such as COPD.

Highly attractive commercial opportunity

US and EU-targeted market research supports peak sales potential exceeding \$2 billion, based on the target product profile.

High healthcare costs for hospitalised patients under the current standard of care underpin a strong pharmacoeconomic case for SNG001.

This commercial proposition is further strengthened by a strategic partnership incorporating a world-class proprietary aerosol delivery platform with device exclusivity, adding to patents and data/marketing exclusivity to create meaningful in-market protection for the originator.



Post-hoc per protocol subgroup analyses

Phase 3 SPRINTER study in Covid-infected patients: ERJ Open Research 2023 9(2): 00605-2022
Respiratory compromised: O₂ Saturation ≤92% or RR ≥21 breaths/min

Differentiated route of delivery with broad clinical utility

SNG001 is an inhaled formulation of interferon-beta (IFN-β) delivered directly to the lungs – the primary site of infection. IFN-β is a naturally occurring protein which orchestrates the body's antiviral immune responses.

Unlike direct-acting antiviral drugs which target specific viruses, SNG001 is a broad-spectrum host-directed antiviral, which enhances pan-viral immunity.

SNG001 consequently has potential clinical utility in patients impacted by a broad range of respiratory viruses including influenza, respiratory syncytial virus (RSV), rhinovirus, coronaviruses (including SARS-CoV-2), parainfluenza, adenovirus and human metapneumovirus (HMPV).

Clinical validation and strategic relevance

Phase 2 and phase 3 trials support SNG001 positioning in severe respiratory infections; with highly encouraging efficacy signals (45-80% reduction in disease progression and mortality) in high-risk COVID patients.

Evidence is also supportive of a potentially high-value positioning in the context of pandemic preparedness.

Robust clinical and non-clinical evidence , supported by strong IP position

Proof of mechanism and proof of principle established based on target engagement, biomarker and anti-viral efficacy from in vitro, non-clinical and clinical studies.

Target clinical profile is underpinned by studies in which more than 750 patients received SNG001, demonstrating a favourable safety profile.

Global clinical trials were conducted by Synairgen, Astra Zeneca and US National Institute of Health (NIH), in asthma, COPD and COVID-infected patients.

Deal opportunity

License or acquisition of phase 2 ready asset

For further information please contact joseph.colliver@synairgen.com

Potential to utilise significant tax losses, and R&D tax credit claim